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Abstract 
BACKGROUND: Based on the Biopharmaceutics Classification System (BCS) system, irbesartan is a drug that 
belongs to the class II BCS group which has limitations in terms of dissolution rates with low bioavailability of 26% 
-60%. These limitations to bioavailability can be overcome by solid dispersion with hydrophilic matrices such as 
Poloxamer. Irbesartan is an angiotensin receptor blocker. At present, it is widely used in dealing with hypertension 
due to endothelial dysfunction. 
AIM: This study aims to determine endothelial function blood markers can be examined, such as adhesion 
molecules (ICAM-1) and IL-8 pro-inflammatory cytokines. 
MATERIAL AND METHODS: Research on the effects of irbesartan-poloxamer-188 solid dispersion on ICAM-1 
and IL-8 in hypertensive rats has been carried out. The formation of solid dispersion through dissolution method 
while induction of hypertension using 2.5% NaCl and prednisone 1.5 mg/Kg BB orally in 3 treatment groups, 
irbesartan dose was 13.5 mg/kg. The parameters observed were serum ICAM-1 and IL-8 levels. 
RESULTS: The result showed that the solid dispersion of irbesartan-poloxamer-188 could reduce ICAM-1 and IL-
8 levels in hypertensive rats which differed significantly from the positive control group (p < 0.05). 
CONCLUSION: This study concluded that the solid dispersion of irbesartan-poloxamer-188 effects and decreases 
ICAM-1 levels in the serum of hypertensive rats. Solid dispersion of irbesartan-poloxamer-188 can influence and 
reduce IL-8 in the serum of hypertensive rats. 
 
 
 
 
Introduction 
 
Based on the Biopharmaceutics Classification 
System (BCS) system, irbesartan is a drug that 
belongs to the class II BCS group, which has 
limitations in terms of dissolution rate [1], [2]. 
Availability of irbesartan is reported to be 26% [3] and 
60% [4]. This limitation of bioavailability has been 
overcome by the solid dispersion of irbesartan made 
with dextrose water-soluble matrix, the method of 
making solid dispersion is done by grinding and 
smelting method [5], formulation and evaluation of 
irbesartan liquid-solid tablets to improve irbesartan 
dissolution and bioavailability [2]. 
Another study of solid dispersion technology 
using super disintegrant sodium starch glycolate, 
crospovidone, croscarmellose sodium and 
microcrystalline cellulose [3]. The latest study was 
comparing the dissolution rate of 2 methods of making 
irbesartan tablets namely wet granulation technique 
and sublimation technique [6].  
To improve the effectiveness of treating 
hypertension using irbesartan, it is necessary to look 
for new polymers. Poloxamer-188 is often considered 
a functional excipient because it is an important 
component in the formulation. Regarding the 
amphiphilic structure possessed by this surfactant, it 
is widely used in the industry. In the study of 
irbesartan, solid dispersion with various comparisons 
of poloxamer-188 the best dissolution rate was 
obtained at a ratio of 2:1 [7]. 
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In the inflammatory process, the endothelial 
surface will express adhesion molecules such as 
vascular cell adhesion molecule-1 (VCAM), 
intercellular cell adhesion molecule-1 (ICAM) and 
interleukin-8 (IL-8) [4]. On the other hand, the effect of 
dissolution rate and modification of the crystal 
properties of irbesartan on endothelial cells such as 
intercellular cell adhesion molecule-1 (ICAM) and 
interleukin (IL-8) has not been reported. 
 
 
Material and Methods 
 
Research Materials 
Irbesartan (Dr Reddys), poloxamer-188 
(Merck), ethanol 96%, prednisone, NaCl, NaCMC and 
distilled water, ELISA kits for ICAM-1 and IL-8 
(USCN). 
 
Instruments 
Vacuum ovens, desiccators, digital analytic 
scales (Denver Instruments), UV-Vis 
spectrophotometers (UV-1700 PharmaSpec), ELISA 
reader. 
 
Animal Experiments 
White mice were weighing between 200-300 
grams many as 24 (Rattus norvegicus) Wistar strain 
(Laboratory of Pharmacology), Faculty of Pharmacy, 
Andalas University, Padang.  
 
Acclimatised animals  
For the next 7 days were grouped into 4 
groups. Three groups of experimental animals were 
given induction with 2.5% NaCl and prednisone 1.5 
mg/kg body weight as much as 2 mL orally for 2 (two) 
weeks; then the experimental animals were given a 
test preparation orally at a dose of 13.5 mg/kg for 1 
(one) week. Each group consisted of 6 rats and 
treated as follows: Group I as a negative control, was 
given standard food and drink, group II as a positive 
control, standard food and drinks were given and 
given induction, group III as a test group was given 
standard food and drinks and inducers and irbesartan 
non-dispersion dose of 13.5 mg/kg, group IV as a test 
group given standard food and drink and induction 
and solid dispersion of irbesartan the dose was 
equivalent to 13.5 mg/kg. Blood is taken from the eye 
vein by 1.5 ml at certain minutes. Then the separation 
between serum and blood objects was carried out, the 
serum was stored in a refrigerator and the storage 
cabinet for a sample temperature of -40°C for further 
analysis. 
Test for Irbesartan Solid Dispersion 
 Activity against ICAM-1 levels 
All reagents are prepared, use well, according 
to the number of wells plate used and labelled. Well 
plate for standard solutions determined, blanks and 
samples, made 7 wells for standards and 1 for blanks, 
added 100 µL of each standard solution, blanks, and 
samples into appropriate wells, covered with 
incubation plate sealers for 2 hours at 37°C. The 
solution of each well was removed and not washed 
and added 100 µL of the working solution to detect the 
reagent in each well and incubated for 1 hour at 37°C 
after being covered with plate sealer.  
The supernatant was removed and washed 
with 350 µL of wash buffer, with 3 x inverted plates. 
Next 100 µL of reagent B working solution was added 
to each well; the plate sealer was closed, incubated 
for 30 minutes at 37°C. The washing process was 
repeated up to 5 times, added 90 µL of the substrate 
solution to each well, covered with a new plate sealer 
and incubated for 15 minutes at 37°C and protected 
by the light the solution would turn blue. Fifty µL stop 
solution is added to each well, so the solution turns 
yellow. Then the microplate reader is traced with an 
ELISA at a wavelength of 450 nm to determine its 
optical density value. The results of ICAM-1 level 
determination, in each rat serum at a specified time 
compared to each experimental group. 
 
Examination of Levels of IL-8 
All reagents are prepared and use wells 
according to the number of wells used and labelled. 
Well for standard solutions, blanks and samples are 
determined, 7 wells for the standard (1000, 500, 250, 
125, 62.5 and 31.25 pg/mL) are made and 1 for 
blanks, 100 µL of each standard solution is added, 
blank and the sample into the right well, covered with 
a sealer plate and incubated for 1.5 hours at 37°C. 
The solution of each well was removed and not 
washed and added 100 µL of the working solution to 
detect reagent (biotin-labelled antibody) into each well 
and incubated for 1 hour at 37°C after being covered 
with plate sealer. The supernatant was removed and 
washed with 350 µL wash buffer, doing 3x inverted 
plates. Then added 100 µL of the working solution 
(SABC) into each well, covered with a plate sealer 
and incubated for 30 minutes at 37°C. The washing 
process was repeated up to 5 times, added 90 µL 
TMB substrate solution to each well, covered with 
plate sealer new and incubated for 15 minutes at 37°C 
and protected by the light the solution would turn blue. 
50 µL stop solution is added to each well, so the 
solution turns yellow. The microplate reader is then 
run by using ELISA at a wavelength of 450 nm to 
determine its optical density value. The results of IL-8 
level determination, in each rat serum at a specified 
time compared to each experimental group. 
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Statistical analysis 
The results of the non-dispersion evaluation 
of irbesartan and solid dispersion of irbesartan-
poloxamer-188 on serum ICAM-1 and IL-8 levels were 
analysed using statistics IBM SPSS version 19. 
Normal distribution tests are carried out using the 
Saphiro Wilk test. If the value of sig. > 0.05, then the 
data is normally distributed. For further analysis, one-
way parametric (ANOVA) is conducted. To determine 
the significance of the treatment, the Bonferroni Post 
Hoc test was carried out. 
 
Research Ethics Requirements 
The approval of the Ethics Commission of the 
Faculty of Medicine, Unand Padang with ethical 
clearance No. 395/KEP/FK/2017. 
 
 
Results 
 
Effect of giving irbesartan solid dispersion 
 on ICAM-1 levels 
The measurement results of the average 
ICAM-1 levels of each negative control group rat 
were: 5.97 ± 2.32 ng/mL, the positive control group 
were: 16.68 ± 1.30 ng/mL, the group of mice given the 
preparation irbesartan non-dispersion is 13.11 ± 2.48 
ng/mL and the group of rats given irbesartan-
poloxamer -188 solid dispersion preparation is 9.54 ± 
1.04 ng/mL.  
Table 1: Results of ICAM-1 examination in rat serum 
NO I (ng/mL) II (ng/mL) III (ng/mL) IV (ng/mL) 
1 7.36 17.01 12.99 8.63 
2 7.62 18.42 9.82 10.79 
3 3.56 17.36 13.43 10.13 
4 7.62 16.61 16.83 9.65 
5 2.46 17.19 14.50 7.97 
6 7.22 14.45 11.06 10.046 
X ± SD 5.97 ± 2.32 16.68 ± 1.3 13.11 ± 2.48 9.54 ± 1.04 
 
These results showed that after induction, 
there was an increase in ICAM-1 levels in the positive 
control group whereas after irbesartan administration 
both non-dispersion and solid dispersion ICAM-1 
levels decreased, as shown in Table 1. 
 
Figure 1: Levels of ICAM-1 in treatment animal group; I) Negative 
control; II) Positive control; III) Non-dispersion of irbesartan; IV) 
Solid dispersion of irbesartan 
Effect of treatment on IL-8 levels 
The administration of inducible substances in 
the positive control group caused an increase in IL-8 
levels in the blood.  
Table 2: Results of IL-8 examination in rat serum 
NO I (pg/mL) II (pg/mL) III (pg/mL) IV (pg/mL) 
1 43.88 52.29 49.47 41.56 
2 38.19 50.04 46.65 41.01 
3 39.89 50.04 50.60 44.96 
4 39.32 50.60 42.71 45.53 
5 40.45 53.98 46.09 45.53 
6 43.27 52.86 42.14 47.22 
X±SD 40.83 ± 2.26 51.63 ± 1.65 46.27 ± 3.43 44.30 ± 2.46 
  
Decreased level of IL-8 was found in the 
treatment group after induction and administration of 
irbesartan non-dispersion and solid dispersion of 
irbesartan (Table 2 and Figure 2). 
 
Figure 2: Levels of IL-8 in treatment animal group; I) Negative 
control; II) Positive control; III) Non-dispersion of irbesartan; IV) 
Solid dispersion of irbesartan 
 
 
Discussion 
 
ICAM-1 level 
The results showed that after induction, there 
was an increase in ICAM-1 levels compared to 
negative controls of 16.85 and 5.47 ng/ml. 
Hypertension is an inflammatory process that involves 
the migration and accumulation of cells from innate 
and adaptive immune responses into the interstitium 
of blood vessels by releasing cytokines and increasing 
oxidative stress. Oxidative stress which plays a role in 
the pathogenesis of endothelial dysfunction in 
hypertension is from nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, integrin 
kinase 1 as a mechanism for the reduction in vascular 
superoxide production due to hypertension [8], [9]. 
The inflammatory process that occurs with 
changes in blood vessels that arise quickly and in the 
short term. This response occurs because the 
mediators of bradykinin and histamine produced by 
local mast cells cause vasodilation and increased 
permeability. This permeability phase occurs within a 
few minutes. After 30-60 minutes, there is a 
marginalisation of neutrophils which group along the 
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endothelium in the injury area, followed by the 
migration of blood fertilisers. The migration process 
occurs through the process of margination, adhesion, 
rolling (grinding), stop rolling and diapedesis [10]. 
At the stage of the process of marginalisation, 
the activated macrophages will produce mediators of 
proinflammatory cytokines, namely IL-1 and TNF-α. 
Furthermore, TNF-α will induce vascular endothelial 
cells to express adhesion molecules, namely selectin, 
integrin, immunoglobulin superfamily (ICAM-VCAM, 
mucin-like molecule, and CD44. There are three types 
of ICAM namely ICAM-1, ICAM-2, and ICAM-3. ICAM 
-1 and ICAM-2 are expressed by endothelial cells and 
also APC, where these bonds allow lymphocytes to 
migrate through the walls of blood vessels and there 
is a weak involvement between the molecules so that 
the leukocytes attach to endothelium [10]. 
In the rolling stage, the weak attachment 
between leukocytes and endothelium will be stronger, 
so that the strength of the bloodstream cannot release 
this bond. The attachment between leukocytes and 
endothelium becomes increasingly strong because of 
activation by chemotactic factors such as leukotriene 
B4, platelet-activating factor and IL-8 by increasing 
the affinity of leukocyte adhesion molecules for 
endothelial adhesion molecules The higher the blood 
pressure, the inflammatory response that occurs will 
also increase to protect the body from cell injury and a 
sustained inflammatory response will increase various 
proinflammatory cytokines, ICAM molecules and 
chemotactic factors IL-8 [10], [11]. 
The mean ICAM-1 levels from the group given 
irbesartan non-dispersion and solid dispersion of 
irbesartan-poloxamer-188, decreased by 13.106 
ng/mL and 10.2014 ng/mL when compared to positive 
controls (16.847 ng/ml), but the results of the decline 
ICAM-1 levels did not reach the same value as the 
negative control (5.474 ng/ml). This is because 
animals that have experienced endothelial dysfunction 
so that recovery takes time. 
Irbesartan, as one of the angiotensin blocker 
receptor drugs in the form of non-dispersion and solid 
dispersion, can inhibit the angiotensin II response 
binding to specific angiotensin receptors. Finally, the 
administration of this drug can improve endothelial 
function, increase vasodilator mediators and increase 
NO bioavailability and reduce the concentration of 
CRP (C-reactive Protein) and inflammatory markers 
such as IL-6, IL-1, ICAM and other factors like 
chemokine IL-8 [12]. 
The results of one-way analysis of variance 
analysis (ANOVA) on examination of ICAM-1 levels in 
experimental animals showed a significant difference 
between the groups given irbesartan to the positive 
control group. Based on the results of the Post Hoc 
Bonferroni statistic, there was a significant effect 
between negative controls with positive controls and 
non-dispersion groups and no significant effect on the 
solid dispersion group. 
The results of the research that have been 
conducted show that the solid dispersion with 
poloxamer-188 carriers has an effect of decreasing 
the average ICAM-1 serum level with ICAM-1 levels 
lower than irbesartan non-dispersion. This is related to 
changes in the physicochemical properties of 
irbesartan can increase the rate of dissolution of the 
drug, with an increase in the dissolution rate of a drug 
and absorption of the drug so that the expected effect 
is also achieved [13]. 
 
Level of IL-8 
The mean value of IL-8 levels from the group 
given irbesartan non-dispersion preparation and solid 
dispersion of irbesartan-poloxamer-188 decreased by 
46.28 pg/mL and 42.80 pg/mL when compared to 
positive controls (51.63 pg/ml), but the result of a 
decrease in IL-8 levels has not reached the same 
value as the negative control (40.83 pg/ml). 
The results of the research that have been 
carried out show that the solid dispersion with 
poloxamer-188 carriers has an effect of decreasing 
the serum levels of IL-8 with IL-8 levels which are 
lower than non-dispersible irbesartan. This is because 
there has been a change in the physicochemical 
properties of irbesartan so that solubility, dissolution, 
and bioavailability have increased [13]. The powder X-
ray analysis showed the decreasing in peak intensity 
at 2θ = 12.34° from 6345.9 to 2915.3, which indicates 
the formation of a crystal lattice that has a degree of 
symmetry. Decreasing the intensity of the interference 
peak shows changes in the degree of crystallinity so 
that it will increase its solubility [7]. 
The results of one-way analysis of variance 
analysis (ANOVA) on IL-8 levels in experimental mice 
showed a significant difference between the groups 
given the preparation to the positive control group. 
Based on the results of the Post Hoc Bonferroni 
statistic with positive and non-dispersion controls, the 
significant influence between negative controls with 
positive control and non-dispersion irbesartan was 
significant (p < 0.05) and did not significantly influence 
the solid dispersion group (p > 0.05). 
In this study, the result showed that the solid 
dispersion of irbesartan could affect the 
physicochemical properties of irbesartan, decreasing 
the level of ICAM-1 and IL-8 levels in the serum of 
hypertensive mice. Decreased levels of ICAM-1 and 
IL-8 showed a decrease in the level of inflammation in 
endothelial cells so that the permeability of endothelial 
cells be better. This is proven by previous studies of a 
decrease in mice blood pressure and an increase in 
serum NO levels [7]. 
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